Endometrial Cancer: Predictive Models and Clinical Impact

In 2012, worldwide, nearly 320,000 new cases of endometrial cancer were identified which represent approximately 5% of new cancer cases in women.The treatments (surgery, external beam radiotherapy, brachytherapy and chemotherapy) are currently issued by a theoretical risk of recurrence or lymph node metastasis on the basis of a prognosis. The risk is obtained from prognostic or predictive factors (clinical, histological, imaging, biological). However, even combined, these factors or these classifications are currently limited and insufficient to account for the endometrial cancer heterogeneity.For endometrial cancer, modeling methods, prediction and risk stratification based on mathematical models have been developed in recent years. These tools aim to promote personalized treatments. The main challenge is the integration of these various methods to optimize our preventive strategies, information and treatment. Many predictive models have been published to estimate the risk of recurrence and lymph node metastasis, however, a small part of them is sufficiently relevant and clinical utility.The optimization runs are multiple and varied raising the possibility in the near future a place for these mathematical models. The rise of genomics is likely to provide a more detailed molecular characterization of the disease and its heterogeneity.